Patent application number | Description | Published |
20090022817 | METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION - A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. | 01-22-2009 |
20090035381 | ELECTROSPRAYING METHOD FOR FABRICATION OF PARTICLES AND COATINGS AND TREATMENT METHODS THEREOF - Electrospray systems and modified electrospray systems for the fabrication of core-shell particles for controlled-release and/or sustained-release treatment and delivery are herein disclosed. The electrospray system may include between one and a plurality of co-axially situated tubes. Each tube may be electrically connected to a power supply wherein a voltage may be applied thereto. Core-shell particles may be collected on a collection target, which may be a wet or dry collector, and electrically connected to the power supply. Core-shell particles and methods of manufacture are also disclosed. The precursors of the core-shell particles may be polymer- or biomacromolecule-based solutions and may include at least one treatment agent incorporated therein. The number of “core” particle(s) within the “shell” may vary and may provide different treatment agent release profiles depending on the material and/or chemical characteristics of the polymer and/or biomacromolecule used. Methods of treating a condition are also disclosed. A treatment may include delivery of a plurality of core-shell particles which include a treatment agent to a treatment site. Delivery may be performed by a surgical procedure or by a non-invasive procedure such as catheter delivery. | 02-05-2009 |
20090075933 | CYTOCOMPATIBLE ALGINATE GELS - The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy. | 03-19-2009 |
20100004627 | NEEDLE CATHETER WITH AN ANGLED DISTAL TIP LUMEN - A needle catheter configured for injecting an agent into a wall of a patient's body cavity, which directs a needle from the distal tip of the catheter into the wall of the body cavity at an angle relative to the axis of the shaft. The resulting angled injection pathway improves the retention of the agent in the body cavity wall, while keeping a distal section of the catheter substantially perpendicular to the body cavity wall for optimal push against the tissue at the injection site. | 01-07-2010 |
20100196313 | Modified Two-Component Gelation Systems, Methods of Use and Methods of Manufacture - Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region. | 08-05-2010 |
20100196314 | Modified Two-Component Gelation Systems, Methods of Use and Methods of Manufacture - Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region. | 08-05-2010 |
20120237477 | METHODS AND COMPOSITIONS FOR TREATING POST-MYOCARDIAL INFARCTION DAMAGE - Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area. | 09-20-2012 |
20120251508 | CYTOCOMPATIBLE ALGINATE GELS - The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy. | 10-04-2012 |
20120252089 | CYTOCOMPATIBLE ALGINATE GELS - The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy. | 10-04-2012 |
20130040356 | CYTOCOMPATIBLE ALGINATE GELS - The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy. | 02-14-2013 |
20150017265 | METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION - A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. | 01-15-2015 |